In a recent transaction, Sarah Cavanaugh, the Senior Vice President of Corporate Affairs & Administration at Celldex (NASDAQ:CLDX) Therapeutics, Inc. (NASDAQ:CLDX), sold a significant amount of company stock. The transaction, which took place on May 30, 2024, involved the sale of 20,853 shares at an average price of $33.7282 per share, resulting in a total value of approximately $703,334.
The sale was conducted in multiple transactions at prices ranging from $33.465 to $34.06 per share. Following the sale, Cavanaugh retained 1,860 shares of Celldex stock. In addition to the sale, Cavanaugh also acquired shares through option exercises on the same day. She exercised options to buy 10,750 shares at $2.78 each and another 10,103 shares at $9.0165 each, totaling around $120,978 in exercised options. After these transactions, her total ownership in the company increased to 22,713 shares.
The options exercised by Cavanaugh were part of the company's incentive stock option plan and were fully vested as of June 19, 2023, and June 13, 2022, respectively. It's also noted that her ownership includes 576 shares acquired under the Celldex Therapeutics , Inc. 2004 Employee Stock Purchase Plan.
The transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission, with a signature by Sam Martin, attorney-in-fact for Sarah Cavanaugh, dated June 3, 2024.
Celldex Therapeutics, Inc., headquartered in Hampton, New Jersey, operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies for the treatment of cancer and other difficult-to-treat diseases. The company's stock is traded on the NASDAQ under the ticker symbol CLDX.
InvestingPro Insights
As Celldex Therapeutics (NASDAQ:CLDX) navigates the biopharmaceutical landscape, recent market data provides a perspective on the company's financial health and stock performance. The company's market capitalization stands at $2.22 billion, reflecting its current valuation in the market. Despite the challenges faced in the industry, Celldex holds a strong cash position relative to its debt, which can be a reassuring sign for investors looking at the company's balance sheet resilience. This is underscored by one of the InvestingPro Tips, noting that the company holds more cash than debt.
Another aspect to consider is the company's stock performance. Recent metrics indicate that the stock has experienced significant volatility, with a 1-week total price return of -9.8% and a 1-month total price return of -21.76%. This volatility is also highlighted by another InvestingPro Tip, which points out that the stock price movements are quite volatile. Additionally, the Relative Strength Index (RSI) suggests that the stock is currently in oversold territory, which could interest investors looking for potential entry points.
For those looking to delve deeper into Celldex Therapeutics' financials and stock analysis, InvestingPro offers a comprehensive set of tools and additional tips. In fact, there are 13 more InvestingPro Tips available that provide further insights into the company's performance and prospects. Interested readers can explore these tips by visiting the dedicated Celldex page on InvestingPro. Plus, by using the coupon code PRONEWS24, users can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to InvestingPro, gaining access to an even broader array of investment analytics and data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.